ITZ analogue

ITZ Analogue is a preclinical-stage oral small molecule being developed by Inhibitor Therapeutics for the treatment of Basal Cell Carcinoma (BCC). It is a next-generation analogue of the antifungal drug itraconazole, which has been repurposed as a potent inhibitor of the Hedgehog (Hh) signaling pathway. The Hedgehog pathway is a key driver in the pathogenesis of BCC, and while first-generation Hh inhibitors like vismodegib and sonidegib target the Smoothened (SMO) protein, resistance often develops through mutations in the SMO binding pocket. ITZ Analogue is designed to inhibit SMO through a mechanism or binding site distinct from that of standard-of-care SMO antagonists, potentially providing a therapeutic alternative for patients with refractory or resistant disease.

Other names

ITZ Analogue BCCItraconazole analogueITZ-analogue